1 rich Libsyn https://www.libsyn.com 90 600 In patients with Type 2 diabetes and&amp;nbsp;established&amp;nbsp;atherosclerotic cardiovascular disease (ASCVD), tirzepatide was non‑inferior to dulaglutide for major cardiovascular events while providing superior kidney protection, lower all‑cause mortality, and greater reductions in HbA1c and body weight. Compared with dulaglutide, a GLP‑1 receptor agonist, tirzepatide&amp;nbsp;demonstrated&amp;nbsp;broader metabolic and clinical benefits. By using dulaglutide as the active comparator rather than a placebo, the trial&amp;nbsp;demonstrated&amp;nbsp;tirzepatide’s strong cardiovascular and metabolic profile, supporting its potential for broader use beyond diabetes management.&amp;nbsp; In this interview,&amp;nbsp;Dipti&amp;nbsp;Itchhaporia&amp;nbsp;MD,&amp;nbsp;MACC&amp;nbsp;and Stephen Nicholls, MBBS,&amp;nbsp;PhD,&amp;nbsp;FACC discuss&amp;nbsp;the SURPASS-CVOT Trial&amp;nbsp;(Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events).&amp;nbsp;&amp;nbsp;&amp;nbsp; ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research http://accelaccorg.libsyn.com/website <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/39887030/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/197896920